1. Home
  2. KLAR vs IMVT Comparison

KLAR vs IMVT Comparison

Compare KLAR & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Klarna Group plc Ordinary Shares

KLAR

Klarna Group plc Ordinary Shares

HOLD

Current Price

$19.25

Market Cap

7.7B

Sector

Finance

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$38.91

Market Cap

8.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KLAR
IMVT
Founded
2005
2018
Country
United Kingdom
United States
Employees
2831
N/A
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7B
8.0B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
KLAR
IMVT
Price
$19.25
$38.91
Analyst Decision
Buy
Buy
Analyst Count
16
8
Target Price
$38.00
$33.00
AVG Volume (30 Days)
4.5M
1.4M
Earning Date
05-14-2026
05-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$28.56
N/A
Revenue Next Year
$19.93
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.06
$14.32
52 Week High
$47.48
$41.23

Technical Indicators

Market Signals
Indicator
KLAR
IMVT
Relative Strength Index (RSI) 54.63 58.46
Support Level $18.29 $25.13
Resistance Level $22.09 $41.23
Average True Range (ATR) 0.99 1.39
MACD -0.15 -0.26
Stochastic Oscillator 25.26 37.50

Price Performance

Historical Comparison
KLAR
IMVT

About KLAR Klarna Group plc Ordinary Shares

Klarna Group PLC is a technology-driven payments company, with operations spanning multiple countries. It connects consumers and merchants with comprehensive payment solutions and tailored advertising solutions, both online and offline. Its payment solutions provide consumers with more control and flexibility over their payments. It is a digital bank and flexible payments provider building the next-generation AI-powered commerce network.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.

Share on Social Networks: